The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | POET: findings and clinical implications for NSCLC prognosis
Lorenzo Belluomini, MD, PhD, University of Verona, Verona, Italy, discusses the results from the retrospective, multicenter POET study which involved the recruitment of 170 patients and investigated the influence of PDL1 expression on non-small cell lung cancer (NSCLC) prognosis as well as the survival benefit of third line tyrosine-kinase inhibitors (TKIs). Dr Belluomini highlight the results from the POET study demonstrate the negative prognostic impact of PDL1 expression and the survival benefit of osimertinib compared to 1st and 2nd generation TKIs. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
